Loading clinical trials...
Loading clinical trials...
Pediatric Selective Cytopheretic Device (SCD-PED, QUELIMMUNE) for Critically Ill Children With Acute Kidney Injury: A Humanitarian Device Exemption (HDE) Surveillance Registry Protocol
Conditions
Interventions
QUELIMMUNE (SCD-PED)
Locations
15
United States
Children's of Alabama
Birmingham, Alabama, United States
Lucile Packard Children's Hospital Stanford
Palo Alto, California, United States
UCSF Benioff Children's
San Francisco, California, United States
HealthONE HCA Rocky Mountain Children's Hospital
Denver, Colorado, United States
Children's Hospital of Atlanta - Arthur M. Blank
Atlanta, Georgia, United States
Children's Hospital of Atlanta - Scottish Rite
Atlanta, Georgia, United States
Start Date
July 19, 2024
Primary Completion Date
May 1, 2026
Completion Date
May 1, 2026
Last Updated
March 23, 2026
NCT06446739
NCT07490808
NCT05806645
NCT06337838
NCT05318196
NCT05728216
Lead Sponsor
SeaStar Medical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions